Quote this publication Share Print

GIOTRIF

-
Opinions on drugs - Posted on Jul 23 2014

Reason for request

Inclusion

   -


Clinical Benefit

Substantial

The actual benefit of GIOTRIF is substantial in the first-line therapy of locally advanced or metastatic non-small cell lung cancer with activating EGFR mutation(s).


Clinical Added Value

no clinical added value

GIOTRIF provides no improvement in actual benefit (level V, non-existent) in the first-line therapy of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).